This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

 (currently amended) A method for the treatment or prophylaxis of a human infected with hepatitis B virus comprising administering in combination or alternation an effective amount of:

β-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β-L-FTC);
1-(2'-deoxy-2'-fluoro-β-L-arabinofuranosyl)-thymine (L-FMAU); and interferon;

or their pharmaceutically acceptable salts or prodrugs, independently optionally in pharmaceutically acceptable carriers.

- 2. (original) The method of claim 1, wherein the B-L-FTC is in substantially pure form.
- (original) The method of claim 1, wherein the B-L-FTC is at least 90% by weight of the B-L-isomer.
- (original) The method of claim I, wherein the \(\beta\)-FTC is at least 95% by weight of the \(\beta\)-Lisomer.
- 5. (currently amended) The method of claim 1, wherein the interferon is selected from the group consisting of interferon alpha, pegylated interferon alpha, interferon alpha-2a, interferon alpha-2b, pegylated interferon alpha-2b ROFERON®-A (interferon

-3-

alpha-2a), PEGASYS® (pegylated interferon alpha-2a), INTRON®A (Interferon alpha-2b). PEG-INTRON® (pegylated Interferon alpha-2b), interferon beta, interferon gamma, interferon tau, interferon omega, consensus interferon, INFERGEN (interferon alphacon-1), OMNIFERON (natural interferon), REBIF (interferon beta-la), omega interferon, oral interferon alpha, interferon gamma-lb, SuperFeron SUPERFERON (natural human multi-subtype IFN-alpha), and HuFeron HUFERON (human IFN-beta).

- 6. (original) The method of claim 5, wherein the interferon is interferon alpha.
- 7. (original) The method of claim 5, wherein the interferon is interferon gamma.
- 8. (original) The method of claim 5, wherein the interferon is interferon beta.